Target Group Reports Substantial Doubt About Going Concern, Ineffective Controls, and Worsening Financials
CBDY has more than doubled off its 52-week low of $0.001 on light trading volume (0.1× avg).
Summary
Target Group Inc. reported substantial doubt about its ability to continue as a going concern, ineffective internal controls, and a significant worsening of financial performance, relying on high-interest related party debt.
Key Events · Corporate Governance and Compliance · CBDY
-
Substantial Doubt About Going Concern
The company's continuation as a going concern is dependent on generating sufficient cash flows or obtaining additional financing, raising substantial doubt about its ability to continue operations.
-
Ineffective Disclosure Controls
Management concluded that disclosure controls and procedures were not effective as of March 31, 2026.
-
Significant Financial Deterioration
Revenue declined from $1.4 million in Q1 2025 to $879,442 in Q1 2026, and net loss increased from $108,213 to $550,356 over the same period. The working capital deficit worsened to $11.3 million.
-
High-Interest Related Party Loan
The company secured a new CDN$330,000 (approximately $236,742 USD) loan from a related party at a high interest rate of 43.26% per annum, with an option for an additional CDN$500,000.
Analysis · CBDY · Life Sciences
Target Group Inc. filed its quarterly report for Q1 2026, raising substantial doubt about its ability to continue as a going concern. Management also concluded that the company's disclosure controls and procedures were ineffective. Financially, the company experienced a significant decline in revenue and a substantial increase in net loss compared to the prior year. The working capital deficit worsened, and the company continues to rely on high-interest related party loans, including a new CDN$330,000 advance at 43.26% interest. The reclassification of a $7.4 million related party loan to current liabilities further highlights immediate liquidity pressures. These issues collectively indicate severe financial distress and significant operational risks for the micro-cap company.
At the time of this filing, CBDY was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.